Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme

Neuropsychopharmacology

Volumn 27, Issue 4, 2002, Pages 587-595

  Zhang, Han Ting ^a   Huang, Ying ^a   Jin, S L Catherine ^b   Frith, Sandra A ^a   Suvarna, Neesha ^a   Conti, Marco ^b   O'Donnell, James M ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Cyclic AMP; Gene knockout; Mice; Phosphodiesterase 4D (PDE4D); Rolipram

Indexed keywords

CYCLIC AMP; DESIPRAMINE; ENZYME; ENZYME INHIBITOR; FLUOXETINE; ISOPRENALINE; PHOSPHODIESTERASE; ROLIPRAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BRAIN CORTEX; CONTROLLED STUDY; DEPRESSION; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME DEFICIENCY; FORCED SWIMMING TEST; GENOTYPE; HETEROZYGOSITY; HIPPOCAMPUS; IMMOBILIZATION; IMMUNOBLOTTING; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TAIL; WILD TYPE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADRENERGIC BETA-AGONISTS; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN; CYCLIC AMP; DEPRESSIVE DISORDER, MAJOR; DOWN-REGULATION; DRUG INTERACTIONS; DRUG TOLERANCE; GENOTYPE; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; PROTEIN ISOFORMS; ROLIPRAM;

EID: 0036790883     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(02)00344-5     Document Type: Article

References (43)

1. Barnette M.S., Underwood D.C. New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease. Curr Opin Pulm Med. 6:2000;164-169.
2. Beavo J.A. Cyclic nucleotide phosphodiesterases. functional implications of multiple isoforms Physiol Rev. 75:1995;725-748.
3. Beck C.H., Fibiger H.C. Chronic desipramine alters stress-induced behaviors and regional expression of the immediate early gene, c-fos. Pharmacol Biochem Behav. 51:1995;331-338.
4. Bobon D., Breulet M., Gerard-Vandenhove M.A., Guiot-Goffioul F., Plomteux G., Sastre-y-Hernandez M., Schratzer M., Troisfontaines B., von Frenckell R., Wachtel H. Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur Arch Psychiatry Neurol Sci. 238:1988;2-6.
5. Cass W.A., Friedemann M.N., deBernardis J.F., Kerkman D.J., Gerhardt G.A. Effects of the putative antidepressant, ABT 200, on the clearance of exogenous norepinephrine in rat cerebellum. Synapse. 21:1995;77-84.
6. Cherry J.A., Davis R.L. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J Comp Neurol. 407:1999;287-301.
7. Cote M., Payet M.D., Rousseau E., Guillon G., Gallo-Payet N. Comparative involvement of cyclic nucleotide phosphodiesterases and adenylyl cyclase on adrenocorticotropin-induced increase of cyclic adenosine monophosphate in rat and human glomerulosa cells. Endocrinology. 140:1999;3594-3601.
8. Dunn A.J., Swiergiel A.H. Behavioral responses to stress are intact in CRF-deficient mice. Brain Res. 845:1999;14-20.
9. Francis S.H., Turko I.V., Corbin J.D. Cyclic nucleotide phosphodiesterases. relating structure and function Prog Nucleic Acid Res Mol Biol. 65:2000;1-52.
10. Fujimaki K., Morinobu S., Duman R.S. Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus. Neuropsychopharmacology. 22:2000;42-51.
11. Hansen G., Jin S., Umetsu D.T., Conti M. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc Natl Acad Sci USA. 97:2000;6751-6756.
12. Heal D.J., Butler S.A., Hurst E.M., Buckett W.R. Antidepressant treatments, including sibutramine hydrochloride and electroconvulsive shock, decrease beta 1- but not beta 2-adrenoceptors in rat cortex. J Neurochem. 53:1989;1019-1025.
13. Houslay M.D. PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol. 69:2001;249-315.
14. Houslay M.D., Sullivan M., Bolger G.B. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family. intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions Adv Pharmacol. 44:1998;225-342.
15. Iona S., Cuomo M., Bushnik T., Naro F., Sette C., Hess M., Shelton E.R., Conti M. Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases. identification and differential expression of immunologically distinct forms in the rat brain Mol Pharmacol. 53:1998;23-32.
16. Jin S.L.C., Richard F.J., Kuo W.P., D'Ercole A.J., Conti M. Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. Proc Natl Acad Sci USA. 96:1999;11998-12003.
17. Keravis T., Komas N., Lugnier C. Cyclic nucleotide hydrolysis in bovine aortic endothelial cells in culture. differential regulation in cobblestone and spindle phenotypes J Vasc Res. 37:2000;235-349.
18. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol. 8:1997;523-532.
19. MacKenzie S.J., Houslay M.D. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. Biochem J. 347:2000;571-578.
20. Manganiello V.C., Murata T., Taira M., Belfrage P., Degerman E. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch Biochem Biophys. 322:1995;1-13.
21. Manji H.K., Drevets W.C., Charney D.S. The cellular neurobiology of depression. Nature Med Rev. 7:2001;541-547.
22. Morris J.S., Smith K.A., Cowen P.J., Friston K.J., Dolan R.J. Covariation of activity in habenula and dorsal raphe nuclei following tryptophan depletion. Neuroimage. 10:1999;163-172.
23. Nibuya M., Nestler E.J., Duman R.S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci. 16:1996;2365-2372.
24. O'Donnell J.M. Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate. J Pharmacol Exp Ther. 264:1993;1168-1178.
25. O'Donnell JM (2000): William Harvey Research Conference on PDE inhibitors: drugs with an expanding range of therapeutic uses. Expert Opin Investig Drugs 9:621-625
26. O'Donnell J.M., Frith S.A. Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases. Pharmacol Biochem Behav. 63:1999;185-192.
27. O'Donnell J.M., Frith S., Wilkins J. Involvement of beta-1 and beta-2 adrenergic receptors in the antidepressant-like effects of centrally administered isoproterenol. J Pharmacol Exp Ther. 271:1994;246-254.
28. Oki N., Takahashi S.I., Hidaka H., Conti M. Short term feedback regulation of cAMP in FRTL-5 thyroid cells. Role of PDE. 4D3(phosphodiesterase activation. J Biol Chem 275):2000;10831-10837.
29. Page M.E., Detke M.J., Dalvi A., Kirby L.G., Lucki I. Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology (Berl). 147:1999;162-167.
30. Perez J., Tardito D., Racagni G., Smeraldi E., Zanardi R. Protein kinase A and Rap1 levels in platelets of untreated patients with major depression. Mol Psychiat. 6:2001;44-49.
31. Perez-Torres S., Miro X., Palacios J.M., Cortes R., Puigdomenech P., Mengod G. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and [3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J Chem Neuroanat. 20:2000;349-374.
32. Porsolt R.D. Animal models of depression. utility for transgenic research Rev Neurosci. 11:2000;53-58.
33. Rodgers R.J., Dalvi A. Anxiety, defence and the elevated plus-maze. Neurosci Biobehav Rev. 21:1997;801-810.
34. Spina D. The potential of PDE4 inhibitors in asthma or COPD. Curr Opin Investig Drugs. 1:2000;204-213.
35. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test. A new method for screening antidepressants in mice Psychopharmacology (Berl). 85:1985;367-370.
36. Takahashi M., Terwilliger R., Lane C., Mezes P.S., Conti M., Duman R.S. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J Neurosci. 19:1999;610-618.
37. Ye Y., Conti M., Houslay M.D., Farooqui S.M., Chen M., O'Donnell J.M. Noradrenergic activity differentially regulates the expression of roliram-sensitive, high-affinity cycdlic AMP phosphodiesterase (PDE4) in rat brain. J Neurochem. 69:1997;2397-2404.
38. Ye Y., Jackson K., O'Donnell J.M. Effects of repeated antidepressant treatment of type 4A phosphodiesterase (PDE4A) in rat brain. J Neurochem. 74:2000;1257-1262.
39. Ye Y., O'Donnell J.M. Diminished noradrenergic stimulation reduces the activity of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase in rat cerebral cortex. J Neurochem. 66:1996;1894-1902.
40. Zhang H.T., Crissman A.M., Dorairaj N.R., Chandler L.J., O'Donnell J.M. Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology. 23:2000;198-204.
41. Zhang H.T., Frith S.A., Wilkins J., O'Donnell J.M. Comparison of the effects of isoproterenol administered into the hippocampus, frontal cortex, or amygdala on behavior of rats maintained by differential reinforcement of low response rate. Psychopharmacology (Berl). 159:2001;89-97.
42. Zhang H.T., O'Donnell J.M. Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats. Psychopharmacology (Berl). 150:2000;311-316.
43. Zhang K., Farooqui S.M., O'Donnell J.M. Ontogeny of rolipram-sensitive, low-K(m), cyclic AMP-specific phosphodiesterase in rat brain. Brain Res Dev Brain Res. 112:1999;11-19.